期刊文献+

青霉胺治疗引起肝豆状核变性神经症状加重 被引量:15

The mechanism for neurological symptom deterioration in Wilson' s disease during the treatment of D-penicillamine
原文传递
导出
摘要 目的探讨肝豆状核变性(WD)患者在使用青霉胺治疗过程中出现神经症状加重的原因和机制。方法选取初诊WD患者40例(其中脑型32例,肝型8例),健康对照20名。对WD患者进行神经症状评分,测定脑脊液铜、血清铜、24h尿铜、脑脊液和血清神经元特异性烯醇化酶(NSE)、血脑屏障指数(AR值)。使用青霉胺治疗3个月后,再次进行神经症状评分,用相同方法测定以上指标。所有数据进行统计学分析。结果15例(46.9%)脑型WD患者使用青霉胺治疗后出现神经症状加重。症状加重的WD患者治疗后脑脊液铜[(0.083±0.030)mg/L]、脑脊液及血清中NSE[(3.00±1.17)、(6.79±2.20)μg/L]高于治疗前[分别为(0.072±0.027)mg/L,(1.32±0.85)、(3.45±2.09)μg/L,t=3.12、2.53、2.71,P〈0.05],血清铜低于治疗前[治疗前后分别为(0.37±0.09)和(0.25±0.08)mg/L,t=3.17,P〈0.05]。症状加重的患者尿铜排出量显著低于症状改善者。治疗前后AR值[分别为(9.53±3.18)和(12.24±3.17)]差异无统计学意义(t=1.45,P〉0.05)。结论初诊WD患者使用青霉胺后是否出现症状加重与其神经系统病变程度和使用青霉胺治疗的剂量有关。青霉胺治疗早期神经症状加重的原因可能是脑铜的增加、神经元新近的损伤和坏死以及铜从中枢神经系统排出困难。 Objective To explore the mechanism of the secondary deterioration of neurological symptoms in Wilson' s disease (WD) at early stage of treatment using D-penicillamine. Methods Forty non-treated WD patients, 32 of encephalic and 8 hepatic type respectively, were enrolled in the study. Their neural symptoms were scored using modified Young grade. Cerebrospinal fluid (CSF) copper, serum copper, urinary copper, neuron specific enolase (NSE) in CSF and the albumin ratio CSF/serum (AR) were measured at the same time. After 3 months of treatment with D-penicillamine, neural symptoms of patients were scored again. All dates were analyzed. Results After 3 months of treatment with D- penicillamine, 15 patients (46. 9% ) developed a secondary deterioration in neurological symptoms. The concentration of copper and the NSE in CSF of patients whose neural symptom was increasingly deteriorated. The serum copper declined after treatment( (0. 37 ±0. 09) vs (0. 25 ±0.08) mg/L, t =3. 17, P 〈0. 05). The 24 hours urinary copper of patients whose symptoms had deteriorated was much lower than that of patients who had not. No significant change was found in AR ratio before and after the treatment (9. 53± 3.18vs 12.24±3.17) in the worsened group (t =1.45, P〉0.05). Conclusions The degree of the injury in the neural system and the dose of penicillamine may affect the deterioration of the neural symptom.The reason why neural symptoms worsens may be increased CSF copper, the newly developed necrosis of the neurons and the difficulty of copper clearance from neural system.
出处 《中华神经科杂志》 CAS CSCD 北大核心 2008年第10期674-677,共4页 Chinese Journal of Neurology
关键词 肝豆状核变性 青霉胺 磷酸丙酮酸水合酶 Hepatolenticular Penicillamine Copper Phosphopyruvate hydratase
  • 相关文献

参考文献10

  • 1Brewer GJ, Terry CA, Aisen AM, et al. Worsening of neurologic syndrome in patients with Wilson' s disease with initial penicillamin therapy. Arch Neurol, 1957, 44: 490-493.
  • 2Ping CC, Hassan Y, Aziz NA, et al. Discontinuation of penicillamine in the absence of ahernative orphan drugs ( trientinezinc): a case of decompensated liver cirrhosis in Wilson' s disease. J Clin Pharm Ther, 2007, 32: 101-107.
  • 3Stuerenburg HJ. CSF copper concentrations, blood-brain barrier function, and coeruloplasmin synthesis during the treatment of Wilson' s disease. J Neural Transm, 2000, 107 : 321-329.
  • 4Medici V, Trevisan CP, D' Inca R, et al. Diagnosis and management of Wilson' s disease: results of a single center experience. J Clin Gastroenterol, 2006, 40 : 936-941.
  • 5梁秀龄,陈曦,李洵桦,黄丽,石铸,汤其强.肝豆状核变性临床若干问题[J].中华神经科杂志,2005,38(1):57-59. 被引量:54
  • 6Lee VD, Northup PG, Berg CL. Resolution of decompensated cirrhosis from Wilson' s disease with zinc monotherapy : a potential therapeutic option? Clin Gastroenterol Hepatol, 2006, 4: 1069- 1071.
  • 7Seo JK. Wilson disease : an update. Korean J Hepatol, 2006, 12 : 333 -363.
  • 8Parnetti L, Palurnbo B, Cardinali L, et al. Cerebrospinal fluid neuron-specific enolase in Alzheimer' s disease and vascular dementia. Neurosci Lett, 1995, 183 : 43-45.
  • 9Porzio S, Iorio R, Vajro P, et al. Penicillamine-related neurologic syndrome in a child affected by Wilson disease with hepatic presentation. Arch Nuerol, 1997, 54:1166-1168.
  • 10黄丽,李洵桦,梁秀龄,李爱萍,庄甲军.各种辅助检查对肝豆状核变性的诊断价值[J].临床神经病学杂志,2006,19(1):8-11. 被引量:25

二级参考文献23

  • 1李洵桦,梁秀龄,刘焯霖,潘锡榜,胡学强,张成,周钰倩,陈嵘,张影如,潘贺葵,欧翠华,卢锡林.957例神经遗传病分析[J].中华医学遗传学杂志,1994,11(6):372-374. 被引量:33
  • 2吕达平,韩咏竹,王训,胡纪源,洪铭范,李凯,胡文彬,杨任民.肝豆状核变性患者肝细胞中P型ATP7B酶水平及功能的研究[J].临床神经病学杂志,2005,18(3):173-175. 被引量:3
  • 3Gitlin JD. Wilson disease. Gastroenterology., 2003,125 : 1868-1877.
  • 4Durand F, Bemrau J, Giostra E. Wilson' s disease with severe hepatic insufficiency: beneficial effects of early administration of D-penicillamine. Gut,2001,48:849-852.
  • 5Brewer GJ. Hedera P, Kluin KJ,et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: Ⅲ. Initial therapy in a total of 55 neurological affected patients and follow up with zinc therapy. Arch Neurol, 2003, 60:379-385.
  • 6Klein D, Arora U, Lichtmannegger J, et al. Tetrathiomolybdate in the treatment of acute hepatitis in an animal model for Wilson disease. J Hepatology, 2004,40:409-416.
  • 7Jumah MA, Majumdar R, Rajeh SA, et al. A clinical and genetic study of 56 Saudi Wilson disease patients: identification of Saudispecific mutations. European J Neurology ,2004, 11 : 121-124.
  • 8梁秀龄.神经系统遗传性疾病[M].第19卷.第1版.北京:人民军医出版社,2001.118.
  • 9Brewer GJ. Recognition, diagnosis and management of Wilson's disease[ J ]. Biology Medicine,2000,223:39.
  • 10胡学强 粱秀龄 刘焯霖.肝豆状核变性纯合子及杂合子的临床生化研究[J].中国神经精神疾病杂志,1986,12:210-210.

共引文献74

同被引文献150

引证文献15

二级引证文献88

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部